CClinicalTrials.gg
CompletedNCT04323241Updated Feb 4, 2021

Association of Placenta Removal Method and Postpartum Leucocytosis

An interventional study of Controlled cord traction in Cesarean Section Complications, sponsored by Haydarpasa Numune Training and Research Hospital. Completed at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Haydarpasa Numune Training and Research Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2019, registered Mar 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Cesarean delivery is one of the most common major abdominal operation in women worldwide. The incidence of postpartum infection has been estimated to be 1-4% after vaginal delivery and 10-20% after Cesarean delivery. Although it is widely performed, manual removal of the placenta is still a conflicting issue due to the risk of post-partum endometritis. All cesarean patients are randomized according to the removal of placenta from the uterus after childbirth; manually (Group 1) or controlled cord traction without putting fingers inside the uterus (Group 2). The aim of this study is to examine whether there is an association between the method of removal of the placenta and postpartum white blood cell increase in nonanemic, singleton, low-risk group of women with term pregnancies, who underwent elective cesarean delivery under general anesthesia.

Read the detailed description

Objective:

Cesarean section is one of the most common major abdominal operation in women worldwide and its rate is increasing every year. Although cesarean birth is considered as safe, it is a potentially morbid procedure with associated risks of hemorrhage, thromboembolic events, infection, and anesthesia risks. The incidence of postpartum infection has been estimated to be 1-4% after vaginal delivery and 10-20% after cesarean section. Manual removal of the placenta is widely accepted by surgeons worldwide. This method enables the surgeon quick intervention. Beside, it helps uterine cavity to be examined for damage and the presence of placental remnants. However, manual removal of the placenta is still a conflicting issue due to the risk of post-partum endometritis, post-partum hemorrhage and abnormal placentation in subsequent pregnancies. It is assumed that controlled cord traction reduces the risk of postpartum hemorrhage and infection.

The aim of this study is to examine whether there is an association between the method of removal of the placenta and increase in postpartum white blood cell counts

After informed consent, all patients are randomized according to the removal of placenta from the uterus after childbirth; manually (Group 1) or controlled cord traction without putting hands inside the uterus (Group 2). Patients are examined regarding to maternal infection. BMI measurement, obstetrics and medical history are recorded. The operative procedures are similar in all patients and followed the same technical steps. In both groups, oxytocin and a first-generation cephalosporin antibiotic are administered intravenously after the delivery of the infant. All uterine incisions were low transverse and all were closed without exteriorisation of the uterus. Complete blood count before delivery, on pastpartum day 1 and 2, fever during hospitalisation, average blood loss during operation and the endometritis cases are recorded. All the patients are asked to come to control on postpartum day 10. Also, patients are asked to come to control if they have fever, abnormal vaginal bleeding, abnormal vaginal discharge, general feeling of sickness and pain in the pelvis. Fever is defined as a temperature above 38.5°C on two consecutive days, excluding the first 24 hours.

02

Conditions studied

  • Cesarean Section Complications

Keywords

  • Placenta removal method
  • postpartum leucocytosis
  • endometritis
  • postpartum anemia
03

In context

Lead sponsor

Haydarpasa Numune Training and Research Hospital is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Nonanemic pregnancies
  • Singleton pregnancies
  • Term pregnancies
  • Elective cesarean sections

Exclusion criteria

Exclusion Criteria:

  • Patients having umbilical cord prolapse,
  • Patients having placenta previa
  • Patients having preterm rupture of mebranes
  • Patients having maternal infection
  • Patients having multiple gestation
  • Patients having antepartum hemorrhage
  • Patients having severe pre-eclampsia
  • Patients having placenta previa
  • Patients having placental abruption
  • Patients having uncontrolled gestational diabetes
  • Heart disease
  • Liver disorders
  • Renal disorders
  • Coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
300 participants (actual)

Study arms

  • No intervention
    control group

    In group 1, plasenta is removed manually. Manual removal of the placenta will be performed by placing surgeon's dominant hand in the uterine cavity and removing the placenta by detaching it from the uterine wall as soon as possible after the delivery of the infant. The emptiness of the uterine cavity is verified manually.

  • Experimental
    Study Group

    In group 2, plasenta is removed by controlled cord traction. Spontaneous removal will be performed by external uterine massage and traction on the umbilical cord are performed to assist spontaneous delivery of the placenta.

    Other: Controlled cord traction

Interventions

  • OtherControlled cord traction

    In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.

06

What researchers measure

Primary outcomes

  1. Change from Baseline Leukocyte Level at Postpartum Day 1

    Measurement of complete blood count

    Time frame: Before delivery and postpartum day 1

  2. Detection of Leukocyte Count

    Measurement of complete blood count

    Time frame: Postpartum day 2

  3. Detection of Number of Patients with Fever

    Body temperature is measured 4 times in a day. Highest temparature will be record on postpartum day 1.

    Time frame: On postpartum day 1

  4. Detection of Number of Patients with Fever

    Body temperature is measured 4 times in a day. Highest temparature will be record on postpartum day 2.

    Time frame: On postpartum day 2

  5. Number of Participants with Postpartum Endometritis

    All the patients are asked to come to control on postpartum day 7. Also, patients are asked to come to control if they have fever, abnormal vaginal bleeding, abnormal vaginal discharge, general feeling of sickness and pain in the pelvis.

    Time frame: Postpartum day 10

Secondary outcomes

  1. Measurement of average blood loss during caesarean section by change from baseline hematocrit level at postpartum day 1.

    Measurement of hematocrit level

    Time frame: Before operation and postpartum day 1

07

Study locations

1 site
  • University of Health Sciences Turkey
    Istanbul, Turkey
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 24, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04323241
Lead sponsor
Haydarpasa Numune Training and Research Hospital
Responsible party
Sevcan Arzu Arinkan (Medical Doctor, Principal Investigator, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Mar 26, 2020
Start date
Oct 1, 2019
Primary completion
Dec 31, 2020
Completion
Jan 20, 2021
Last update
Feb 4, 2021

Study contacts

Sevcan Arzu Arinkan, M.D.
principal investigator · Haydarpasa Numune Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion